Junshi Forms Commercialization JV with Rxilient to Market PD-1 in Southeast Asia

Shanghai Junshi Bio has formed a JV with Singapore’s Rxilient Biotech to commercialize Junshi’s anti-PD-1 drug, toripalimab, in nine Southeast Asian countries. Rxilient, a drug registration/commercialization company, will pay $5 million for a 40% stake in Excellmab, the new JV, and Junshi will contribute the rights for toripalimab in the countries. Junshi pointed out that toripalimab, the first China-developed PD-1 approved in China, is already involved in 30 countries around the globe. It is being tested for 15 indications, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues: